Tyme Technologies to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright on September 9, 2019
September 04, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that...
TYME Announces Abstracts Selected for Presentation at the European Society of Medical Oncology Congress 2019
August 12, 2019 08:00 ET
|
Tyme Technologies, Inc.
SM-88 (racemetyrosine) is an oral, investigational cancer metabolism-based therapy that has demonstrated responses across 15 different cancersNew oral approach aimed at disrupting cancer metabolism in...
Tyme Technologies to Present at BTIG Biotechnology Conference on August 12th, 2019
August 09, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
TYME Provides Business Update and Reports First Quarter Fiscal 2020 Financial and Operating Results
August 08, 2019 08:00 ET
|
Tyme Technologies, Inc.
TYME Presented Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic CancerNYU Langone and TYME Entered...
TYME Announces Abstracts Selected for Presentation at the AACR Special Conference on Pancreatic Cancer
August 07, 2019 08:00 ET
|
Tyme Technologies, Inc.
SM-88 (racemetyrosine) is an oral, investigational cancer metabolism-based therapy that has demonstrated responses across 15 different cancersNew oral approach aimed at disrupting cancer metabolism in...
Tyme Technologies to Present at the 39th Annual Canaccord Genuity Growth Conference on August 7th, 2019
August 01, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
TYME Technologies Announces New Collaboration with NYU Langone to Advance TYME’s Cancer Metabolism-Based Therapy, SM-88
July 29, 2019 08:00 ET
|
Tyme Technologies, Inc.
NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company, announced a new research collaboration with NYU Langone Health to advance the...
REMINDER - TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer
July 08, 2019 08:00 ET
|
Tyme Technologies, Inc.
In this poor prognosis population, SM-88 demonstrated median overall survival (OS) of 6.4 months as of April 25, 2019 Efficacy indicators showed strong correlation with greater overall survival (OS)....
TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer
July 05, 2019 08:00 ET
|
Tyme Technologies, Inc.
In this poor prognosis population, SM-88 demonstrated median overall survival (OS) of 6.4 months as of April 25, 2019 Efficacy indicators showed strong correlation with greater overall survival (OS)....
TYME Announces Abstract Selected for Presentation at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer 2019
June 07, 2019 08:00 ET
|
Tyme Technologies, Inc.
SM-88 (racemetyrosine) is an oral, investigational cancer metabolism-based therapy that has demonstrated responses across 15 different cancersNew oral approach aimed at disrupting cancer metabolism in...